<DOC>
	<DOCNO>NCT01438021</DOCNO>
	<brief_summary>This pilot clinical trial study continuous intraventricular methotrexate treat patient leptomeningeal disease . Drugs use chemotherapy , methotrexate , work different way stop growth cancer cell , either kill cell stop divide . Giving drug directly ventricle may effective treatment patient leptomeningeal disease</brief_summary>
	<brief_title>Continuous Intraventricular Methotrexate Treating Patients With Leptomeningeal Disease</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine pharmacokinetics efficacy continuous intraventricular methotrexate infusion treatment leptomeningeal disease . SECONDARY OBJECTIVES : I . Describe dose limit toxicity . II . Describe pharmacodynamics continuously deliver intraventricular methotrexate . III . Assess response . OUTLINE : Patients receive intraventricular methotrexate continuously day 1-14 . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Meningeal Carcinomatosis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Subjects leptomeningeal carcinomatosis ( solid tumor ) Subjects lymphomatous leukemic meningitis The effect methotrexate develop fetus unknown ; reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control abstinence ) prior study entry six month follow conclusion study participation ; woman become pregnant suspect pregnant participate trial , exclude study inform treat physical immediately Karnofsky Performance Status great 70 % All subject must ability understand willingness sign write informed consent We exclude subject prior intrathecal/intraventricular therapy methotrexate within 6 month Prior therapy methotrexate management leptomeningeal disease Subjects evidence hydrocephalous Subjects intraparenchymal lesion bulky disease Subjects ventriculoperitoneal shunt place Previous history whole brain radiation therapy Subjects , opinion principal investigator , may able comply safety monitoring requirement study include trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>